Germany Summit Reveals Major Breakthroughs in Diabetes Heart and Kidney Care

A study from Germany — specifically the 9th Cardiovascular Outcome Trial (CVOT) Summit hosted by the Forschergruppe Diabetes e.V. at Helmholtz Center Munich — brought together leading endocrinologists, cardiologists, kidney specialists, and primary care doctors in late 2023 to review some of the most significant diabetes drug trials in recent years. The findings discussed at this international congress have direct, meaningful implications for the millions of Americans living with type 2 diabetes, obesity, and related heart and kidney conditions.

What Was Reviewed at the Summit?

Experts gathered virtually on November 30–December 1, 2023, to analyze results from four landmark clinical trials:

• DAPA-MI — examining dapagliflozin (Farxiga), an SGLT2 inhibitor, in heart attack survivors
• SELECT — evaluating semaglutide (Ozempic/Wegovy) for cardiovascular risk reduction in people with obesity but without diabetes
• STEP-HFpEF — studying semaglutide's ability to treat obesity-related heart failure with preserved ejection fraction (HFpEF), a common and difficult-to-treat condition
• CLEAR Outcomes — assessing bempedoic acid, a cholesterol-lowering drug, as an alternative for patients who cannot tolerate statins

Together, these trials point to a new era of diabetes and metabolic care where drugs originally developed for blood sugar control are now proven to protect hearts and kidneys too.

Key Findings in Plain English

One of the summit's most important takeaways is that SGLT2 inhibitors and GLP-1 receptor agonists do far more than lower blood sugar. These medications — already widely prescribed in the US — were shown to meaningfully reduce the risk of major adverse cardiovascular events (MACE), including heart attack, stroke, and cardiovascular death. For US patients whose blood glucose targets typically aim for an A1C below 7% (average blood sugar around 154 mg/dL), these drugs offer protection well beyond glucose numbers alone.

The summit also highlighted growing attention to chronic kidney disease (CKD) management using SGLT2 inhibitors alongside a newer class called non-steroidal mineralocorticoid receptor antagonists (nsMRAs), such as finerenone (Kerendia), which is already FDA-approved.

A Critical Issue: Who Is Included in These Trials?

German and international researchers raised a crucial concern that resonates deeply in the US: clinical trials have historically underrepresented racial and ethnic minority groups, despite these communities facing disproportionately higher rates of diabetes and its complications. The summit stressed that drug effectiveness cannot be assumed equal across all populations without diverse enrollment data — a point directly relevant to Black, Hispanic, and Native American patients in the United States.

Why This Matters for US Patients

This international German summit validates and reinforces what the American Diabetes Association (ADA) and American Heart Association (AHA) have been increasingly recommending in their own guidelines: that SGLT2 inhibitors and GLP-1 agonists should be prioritized for people with diabetes who also have heart disease, kidney disease, or obesity — regardless of blood sugar levels alone. The summit's emphasis on continuous glucose monitoring (CGM) technology also aligns with growing US Medicare coverage expansions for these devices. Additionally, the summit's exploration of connections between diabetes, obesity, fatty liver disease (MASH/NASH), and cancer signals that US doctors may soon need to screen and treat more holistically. Finally, the call for better patient-doctor communication strategies is a reminder that understanding your treatment options — and speaking up about side effects — is key to getting the most from modern diabetes therapies.

About This Research

This summit report was authored by Schnell, Barnard-Kelly, and Battelino, and published in Cardiovascular Diabetology (2024). PMID: 38504284 | DOI: 10.1186/s12933-024-02180-8